## **EAST Search History**

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	1642	2,6-diisopropylphenol or propofol or propofolum	US-PGPUB; USPAT; EPO; DERWENT		OFF	2006/09/19 08:13
S2	888568	injection	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/18 10:20
S3	847	S1 and S2	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/18 10:33
S4	400	polyethylene adj glycol adj "660" adj hydroxystearate or solutol	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 10:27
S5	794	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj ether or glycofurol	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 10:28
S6	3	S3 and S4 and S5	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/18 10:28
S7	413	S1 and S2 @py<="2003"	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/18 10:34
S8	8840	bile adj salt	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2006/09/18 10:34
59	56	S7 and S8	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2006/09/18 10:40
510	4	S4 and S7	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2006/09/18 10:40
511	1642	2,6-diisopropylphenol or propofol or propofolum	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/09/18 13:15

## **EAST Search History**

			<b>-</b>			
S12	888568	injection	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/18 13:15
S13	794	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj ether or glycofurol	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 13:24
S14	34	S11 and S12 and S13	US-PGPUB; USPAT; EPO; DERWENT	AND	OFF	2006/09/18 13:16
S15	8	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj ether	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2006/09/18 13:25
S16	1278	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj glycofurol or tetraglycol or methoxy adj PEG	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 13:31
S17	18	S11 and S12 and S16	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 13:27
S18	1102762	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj glycofurol or tetraglycol or methoxy adj PEG or tetrahydrofurfuryl alcohol PEG ether	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 13:31
S19	1280	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj glycofurol or tetraglycol or methoxy adj PEG or tetrahydrofurfuryl adj alcohol adj PEG adj ether	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 13:31
S20	113	diprivan	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/19 08:17
S21	1665	diprivan or propofol or 2, 6-diisopropylphenol or propofolum	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/19 08:17
S22	1280	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj glycofurol or tetraglycol or methoxy adj PEG or tetrahydrofurfuryl adj alcohol adj PEG adj ether	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/19 08:17

## **EAST Search History**

S23	30	S21 and S22	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/19 08:18
S24	30	S21 and S22	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/19 08:18

9/19/2006 10:01:12 AM C:\Documents and Settings\dclaytor\My Documents\EAST\Workspaces\propofol.wsp

FILE 'HOME' ENTERED AT 10:03:00 ON 19 SEP 2006 => file caplus medline biosis embase COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 0.21 0.21 FILE 'CAPLUS' ENTERED AT 10:03:28 ON 19 SEP 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS) FILE 'MEDLINE' ENTERED AT 10:03:28 ON 19 SEP 2006 FILE 'BIOSIS' ENTERED AT 10:03:28 ON 19 SEP 2006 Copyright (c) 2006 The Thomson Corporation FILE 'EMBASE' ENTERED AT 10:03:28 ON 19 SEP 2006 Copyright (c) 2006 Elsevier B.V. All rights reserved. => s 2,6-diisopropylphenol or propofol or propofolum 39816 2,6-DIISOPROPYLPHENOL OR PROPOFOL OR PROPOFOLUM L1=> s injection or microemulsion 1617420 INJECTION OR MICROEMULSION L2 => s l1 and l2 L3 4299 L1 AND L2 => s polyethylene(w)glycol(w)660(w)hydroxystearate or solutol 362 POLYETHYLENE(W) GLYCOL(W) 660(W) HYDROXYSTEARATE OR SOLUTOL => s tetrahydrofurfuryl(w)alcohol(w)polyethyleneglycol(w)ether or glycofurol or tetraglycol or methoxy(w) PEG 786 TETRAHYDROFURFURYL(W) ALCOHOL(W) POLYETHYLENEGLYCOL(W) ETHER OR GLYCOFUROL OR TETRAGLYCOL OR METHOXY(W) PEG => s 13 and 14 and 15 L6 2 L3 AND L4 AND L5 => d ti au abs so py 1-2 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN L6 ΤI Formulations containing propofol for anesthetic use Bell, Alan R.; Cochrane, Fenella; O'Connor, Geoffrey N.; Rowe, James S. IN A formulation for anesthetic use is described. The formulation contains AB propofol, and may be used to induce and/or maintain anesthesia or sedation in a vertebrae. The formulation addnl. contains a solvent or a combination of solvents and is suitable for mixing with commonly used infusion fluids prior to injection to a patient. The formulation may be terminally sterilized using moist heat in order to assure sterility, and contains no lipid, thereby avoiding complications associated with administration over prolonged periods of time, or to patients with disorders of fat metabolism For example, a solution was formulated containing propofol 1, glycofurol 20, Solutol HS15 10, benzyl alc. 2, ethanol 2 % weight/volume, and water for injection to SO U.S. Pat. Appl. Publ., 12 pp. CODEN: USXXCO

PY

```
L6
       ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
       Injectable 2,6-diisopropylphenol-containing
  ΤI
       anesthetic composition and methods
  IN
       Jee, Ung-kil
       An injectable anesthetic composition in a microemulsion phase is
  AΒ
       disclosed. The composition contains 2,6-
       diisopropylphenol as the active ingredient, together with
       polyethylene glycol 660
       hydroxystearate, tetrahydrofurfuryl alc.
       polyethyleneglycol ether, and an aqueous medium. Methods of
       making and using the injectable anesthetic composition are also disclosed.
       U.S. Pat. Appl. Publ., 9 pp.
  SO
       CODEN: USXXCO
  PY
       2004
       2004
       2004
       2004
       2005
       2005
 => s 13 and 15
 L7
               2 L3 AND L5
 => d ti au so py 1-2
      ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 L7
      Formulations containing propofol for anesthetic use
 TI
 IN
      Bell, Alan R.; Cochrane, Fenella; O'Connor, Geoffrey N.; Rowe, James S.
 SO
      U.S. Pat. Appl. Publ., 12 pp.
      CODEN: USXXCO
 PY
      2005
      2005
      2004
      2004
      ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 L7
      Injectable 2,6-diisopropylphenol-containing
 TI
      anesthetic composition and methods
 IN
      Jee, Ung-kil
U.S. Pat. Appl. Publ., 9 pp.
 SO
      CODEN: USXXCO
 PY
      2004
      2004
      2004
     2004
     2005
     2005
=> s cellulose
L8
        466581 CELLULOSE
=> s 13 and 18
             3 L3 AND L8
=> s ti au abs py so 1-3
L10
             0 TI AU ABS PY SO 1-3
=> d ti au abs py so 1-3
L10 HAS NO ANSWERS
'1-3 ' IS NOT A VALID SEARCH STATUS KEYWORD
Search status keywords:
```

```
NONE ---- Display only the number of postings.
 STATUS -- Display statistics of the search.
 ENTER SEARCH STATUS OPTION (NONE), STATUS, OR ?:19
 'L45' IS NOT A VALID SEARCH STATUS KEYWORD
 Search status keywords:
 NONE ---- Display only the number of postings.
 STATUS -- Display statistics of the search.
 ENTER SEARCH STATUS OPTION (NONE), STATUS, OR ?:none
               0 SEA TI AU ABS PY SO 1-3
 => d 19 ti au abs py so 1-3
 L9
      ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
      Novel encochleation methods, cochleates and methods of use
 ΤI
 IN
      Mannino, Raphael J.; Gould-Fogerite, Susan; Krause-Elsmore, Sara L.;
      Delmarre, David; Lu, Ruying
      The invention generally relates to cochleate drug delivery vehicles.
 AΒ
      Disclose are novel methods for making cochleates and cochleate compns.
      that include introducing a cargo moiety to a liposome in the presence of a
      solvent. Also disclosed are cochleates and cochleate compns. that include
     an aggregation inhibitor, and optionally, a cargo moiety. Addnl., anhydrous
     cochleates that include a protonized cargo moiety, a divalent metal cation
     and a neg. charge lipid are disclosed. Methods of using the cochleate
     compns. of the invention, including methods of administration, are also
     disclosed.
PΥ
     2004
     2005
     2005
     2005
     2006
SO
     PCT Int. Appl., 195 pp.
     CODEN: PIXXD2
     ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
L9
     Injectable 2,6-diisopropylphenol-containing
ΤI
     anesthetic composition and methods
IN
     Jee, Ung-kil
     An injectable anesthetic composition in a microemulsion phase is
AB
                The composition contains 2,6-
     diisopropylphenol as the active ingredient, together with
     polyethylene glycol 660 hydroxystearate, tetrahydrofurfuryl alc.
     polyethyleneglycol ether, and an aqueous medium. Methods of making and using
     the injectable anesthetic composition are also disclosed.
PΥ
     2004
     2004
     2004
     2004
     2005
     2005
SO
     U.S. Pat. Appl. Publ., 9 pp.
     CODEN: USXXCO
    ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
L9
    Biodegradable injectable implants and related methods of manufacture and
TI
TN
    Caseres, Crisofo Peralta; D'Lagarde, Daniel Leon
    This invention is directed to the field of medical implants, and more
AB
    specifically to biodegradable injectable implants and their methods of
    manufacture and use. The injectable implants disclosed herein comprise
    glycolic acid and bio-compatible/bio-absorbable polymeric particles containing
    a polymer of lactic acid. The particles are small enough to be injected
    through a needle but large enough to avoid engulfment by macrophages.
```

injectables of this invention may be in a pre-activated solid form or an

```
activated form (e.g., injectable suspension or emulsion). For example, a
       lyophilized composition was prepared containing glycolic acid 0.07 mg,
  poly(lactic
       acid) spheres 200.0 mg, hydroxypropyl Me cellulose 118.33 mg,
       D-mannitol 170.0 mg, pH stabilizer (phosphate buffer) 0.50 mg, and
       surfactant (Tween 80) 1.20 mg. The composition was activated extemporaneously
       with 5.5 mL water to obtain an injectable preparation
  PY
       2003
       2003
       2003
       2003
       2004
       2004
       2004
       2005
 SO
      PCT Int. Appl., 60 pp.
      CODEN: PIXXD2
 => s pH(w)regulator
 L11
           1080 PH(W) REGULATOR
 => s 13 and 111
 L12
              0 L3 AND L11
 => s acetate
         884590 ACETATE
 L13
 => s 13 and 113
 L14
             31 L3 AND L13
 => d ti au abs so py 1-5
     ANSWER 1 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
      Lipid-based dispersions for drug delivery
     Hu, Ning; Jensen, Gerard M.; Yang, Stephanie; Su-ming, Chiang
 IN
     The invention provides lipid-based dispersion comprising comprising,
AB
     phosphatidylcholine, an anionic phospholipid, up to 1% cholesterol by weight
     of total lipids, and a therapeutic agent, wherein the mean particle size
     measured by dynamic light scattering is <100 nm. The invention also
     provides pharmaceutical compns. comprising such a dispersion as well as
     methods of producing a therapeutic effect in a mammal comprising
     administering an effective amount of such a dispersion.
     Soy-phosphatidylcholine, DSPG, and propofol were dissolved in a
     1:1 mixture of methanol and chloroform at a molar ratio of Soy-PC:DSPG of
     1:0.4 and a weight ratio of (Soy-PC + DSPG):propofol of 10:1.
     Solvents were removed by evaporation and the films were then hydrated in 9%
     sucrose at desired drug concns. and sonicated to form liposomes.
SO
     PCT Int. Appl., 31 pp.
     CODEN: PIXXD2
PY
     2005
     2006
     2005
     2005
     2005
    ANSWER 2 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
     Propofol formulation containing reduced oil and surfactants
    Desai, Neil P.; Yang, Andrew; De, Tapas; Ci, Sherry Xiaopei; Soon-Shiong,
IN
    Sterile, stable pharmaceutical formulations of emulsions of neat
AB
    propofol or propofol dissolved in a solvent and containing
    no preservative are provided that comprise optimal amts. of surfactants
    such as lecithin and solvent such as soybean oil, with a suitable pH range
```

```
to prevent significant growth of microorganisms for at least 24 h after
     extrinsic contamination. The lower amount of oil or absence (oil) in the
     formulation also allows chronic sedation over extended periods of time
     with a reduced chance of lipid overload in the blood. Formulations with
     the following general ranges of components for such propofol
     compns. were prepared as follows: propofol 0.5-5; human serum
     albumin 0.01-3; glycerol 2.25; water for injection qs to 100%.
     U.S. Pat. Appl. Publ., 13 pp.
     CODEN: USXXCO
     2004
    2004
    2005
    ANSWER 3 OF 31 CAPLUS
L14
                            COPYRIGHT 2006 ACS on STN
    Propofol with cysteine
    Tang, Hua; Chen, Hongming; Almarsson, Orn
    The present invention relates to pharmaceutical compns. comprising
    2,6-diisopropylphenol (propofol).
    Compns. of the present invention comprise aqueous and non-aqueous compns. of
    propofol and cysteine or a salt thereof. The propofol
    containing compns. are preferably sterile and are parenterally administered to
    any animal, including humans.
    PCT Int. Appl., 23 pp.
    CODEN: PIXXD2
    2004
    2004
    2004
    2004
    2004
    2005
    2005
    2006
   ANSWER 4 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
    Substituted phenol compounds useful for anesthesia and sedation
    Jenkins, Thomas E.; Ji, Yu-Hua; Wu, Huiwei; Bolton, Jennifer
    Substituted phenol compds. and pharmaceutical compns. containing them, e.g.,
    injections, which are useful for inducing or maintaining
   anesthesia or sedation in a mammal are provided. For example,
   4-methoxycarbonyl-2,6-diisopropylphenol,
   prepared by the reaction of carbon tetrachloride, 2,6-
   diisopropylphenol and methanol, was used for the synthesis of
   4-(2-methoxycarbonylethyl)-2,6-
   diisopropylphenol by its reaction with Et acetate.
   PCT Int. Appl., 41 pp.
   CODEN: PIXXD2
   2003
   2003
   2003
   2003
   2004
   2004
   2005
   ANSWER 5 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
   Novel pharmaceuticals comprising drug conjugates with polypeptide carriers
   Picariello, Thomas
   A pharmaceutical composition comprising a polypeptide and an active agent
   attached to said polypeptide is disclosed.
   PCT Int. Appl., 2059 pp.
   CODEN: PIXXD2
   2003
   2003
```

SO

PΥ

ΤI

ΙN

AΒ

SO

PΥ

TI

IN

AB

so

PΥ

TIIN

AΒ

so

PΥ

2003

```
2006
      2004
      2006
 => s diprivan or propofol or 2,6-diisopropylphenol or propofolum
          39943 DIPRIVAN OR PROPOFOL OR 2,6-DIISOPROPYLPHENOL OR PROPOFOLUM
 => d his
      (FILE 'HOME' ENTERED AT 10:03:00 ON 19 SEP 2006)
      FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:03:28 ON 19 SEP 2006
           39816 S 2,6-DIISOPROPYLPHENOL OR PROPOFOL OR PROPOFOLUM
 L1
         1617420 S INJECTION OR MICROEMULSION
L_2
L3
            4299 S L1 AND L2
             362 S POLYETHYLENE(W)GLYCOL(W)660(W)HYDROXYSTEARATE OR SOLUTOL
L4
L5
             786 S TETRAHYDROFURFURYL (W) ALCOHOL (W) POLYETHYLENEGLYCOL (W) ETHER OR
L6
               2 S L3 AND L4 AND L5
L7
               2 S L3 AND L5
L8
         466581 S CELLULOSE
L9
               3 S L3 AND L8
L10
               0 S TI AU ABS PY SO 1-3
L11
           1080 S PH(W) REGULATOR
L12
              0 S L3 AND L11
L13
         884590 S ACETATE
L14
             31 S L3 AND L13
          39943 S DIPRIVAN OR PROPOFOL OR 2,6-DIISOPROPYLPHENOL OR PROPOFOLUM
L15
=> s 115 and 12
L16 °
         4308 L15 AND L2
=> s 116 and 14 and 15
L17
             2 L16 AND L4 AND L5
=> s 116 and 111
L18
             0 L16 AND L11
=> s 116 and 18
L19
            3 L16 AND L8
```

2003